Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Skye Bioscience Confirms Nimacimab Development After Monlunabant Data
Details : RYI-018 (nimacimab) is a negative-allosteric modulating antibody targeting the CB1. It will undergo clinical phase 2 development for the treatment of patients with obesity.
Brand Name : RYI-018
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 23, 2024
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Skye Bioscience Launches Phase 2 Trial of Nimacimab for Obesity Treatment
Details : Nimacimab is a negative-allosteric modulating antibody targeting the CB1. It will undergo clinical phase 2 development for the treatment of patients with obesity.
Brand Name : RYI-018
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 22, 2024
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Recipient : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
Beacon Biosignals Collaborates with Skye Bioscience to Integrate Sleep Quality Endpoints
Details : The collaboration aims to advance the clinical development of RYI-018 (nimacimab), currently being evaluated in early-stage clinical trials involving patients with obesity.
Brand Name : RYI-018
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 24, 2024
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Recipient : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
Beacon Biosignals Collaborates with Skye Bioscience to Integrate Sleep Quality Endpoints
Details : This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform to better understand the comprehensive impact of Nimacimab on patients with obesity.
Brand Name : RYI-018
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 24, 2024
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
Details : SBI-100 is a cannabinoid receptor type 1 (“CB1”) agonist administered topically onto the eye. It is being evaluated for the treatment of primary open angle glaucoma & ocular hypertension.
Brand Name : SBI-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2024
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Skye Completes Enrollment for Phase 2a of SBI-100 Emulsion in Glaucoma Patients
Details : SBI-100 is a cannabinoid receptor type 1 (“CB1”) agonist administered topically onto the eye. It is being evaluated for the treatment of primary open angle glaucoma & ocular hypertension.
Brand Name : SBI-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : Tetrahydrocannabinol Valine Hemisuccinate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor (CB1). Now it will undergo clinical development for the treatment of patients with obesity and chronic kidney disease.
Brand Name : RYI-018
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : Nimacimab
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SBI-100
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Details : SBI-100 is a cannabinoid receptor type 1 (CB1) agonist administered topically onto the eye. It is being evaluated to lower intraocular pressure and in patients with primary open-angle glaucoma or ocular hypertension.
Brand Name : SBI-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 28, 2023
Lead Product(s) : SBI-100
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nimacimab
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Bird Rock Bio
Deal Size : $20.0 million
Deal Type : Acquisition
Details : Through the acquisition, Skye expand its position as a leading endocannabinoid systemfocused pharmaceutical company by including, Bird Rock's lead asset, nimacimab, a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor...
Brand Name : RYI-018
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : Nimacimab
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Bird Rock Bio
Deal Size : $20.0 million
Deal Type : Acquisition
Lead Product(s) : SBI-100
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : 5AM Ventures
Deal Size : $17.0 million
Deal Type : Financing
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Details : The net financing will be used to advance Phase 2 of SBI-100 OE, a first-in-class, topically-administered CB1 agonist focused on reducing intraocular pressure related to glaucoma and ocular hypertension.
Brand Name : SBI-100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : SBI-100
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : 5AM Ventures
Deal Size : $17.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?